Login to Your Account

$70M License Fee For Phase IIb Capsule

Microbia, Forest Collaborate: Up To $330M For IBS Candidate

By Randall Osborne

Tuesday, September 18, 2007
Microbia Inc.'s potential $330 million deal - $70 million up front as a licensing fee - with Forest Laboratories Inc. for the Phase IIb gastrointestinal drug linaclotide could let the pair jump into the $500 million-plus market gap left earlier this year when Novartis AG pulled its compound for constipative irritable bowel syndrome, Zelnorm, off the shelves due to safety concerns. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription